Showing results for:
Asparaginase erwinia chrysanthemi (recombinant)- rywn
Rylaze® is a component of a multi-agent chemotherapeutic regimen indicated for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
Asparaginase erwinia chrysanthemi (recombinant)- rywn Rylaze®
Rezurock™ is approved for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Rezurock™ Belumosudil
Rolvedon is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
Rolvedon™ Eflapegrastim-xnst
Epoetin alfa is indicated forTreatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapyReduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery.Epogen is not indicated for use:In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapyIn patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cureIn patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusionIn patients scheduled for surgery who are willing to donate autologous bloodIn patients undergoing cardiac or vascular surgeryAs a substitute for RBC transfusions in patients who require immediate correction of anemia
Epogen® Procrit® EPO Epoetin alfa Epoetin alfa-epbx* Retacrit™ *
Filgrastim is FDA approved to Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with feverReduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresisReduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropeniaIncrease survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)
Neupogen® Filgrastim G-CSF Zarxio™ * Filgrastim-sndz* Nivestym™ * Filgrastim-aafi* Releuko* Filgrastim-ayow*
Imetelstat is FDA approved for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
Rytelo Imetelstat
Interferons are substances naturally produced by cells in the body to help fight infections and tumors. They may also be synthetic versions of these substances. Interferon alfa-2a is FDA approved to treat people who have hairy cell leukemia and Philadelphia chromosome positive chronic myeloid leukemia who are minimally pretreated (within 1 year of diagnosis). It may cause a temporary loss of hair. After treatment has ended, normal hair growth should return.
Roferon®-A Interferon alfa-2a
Lenalidomide is FDA approved to treat patients with:Multiple myeloma, in combination with dexamethasoneMultiple myeloma, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalitiesMantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib Previously treated follicular lymphoma (FL), in combination with a rituximab productPreviously treated marginal zone lymphoma (MZL), in combination with a rituximab product Limitations of Use: Revlimid is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials
Revlimid® Lenalidomide
Luspatercept-aamt is FDA approved for the treatment of:Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions. Anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). Limitations of Use: Reblozyl is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.
Reblozyl® Luspatercept-aamt
Methotrexate is FDA approved, alone or with other drugs, to treat people who have acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to prevent ALL from spreading to the CNS. It is also FDA approved to treat people who have advanced non-Hodgkin lymphoma and advanced mycosis fungoides. It may also be used to treat people with other types of blood cancer.
Rheumatrex® Trexall® Methotrexate
Rydapt is FDA approved for the treatment of adult patients with:Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.Limitations of Use:RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Rydapt® Midostaurin
Olutasidenib is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
Olutasidenib Rezlidhia™
Rasburicase is FDA approved for the initial management of plasma uric acid levels in patients with leukemia, lymphoma and solid tumors who are receiving certain types of anticancer therapy expected to result in elevated plasma uric acid.
Elitek® Rasburicase
Remestemcel-L-rknd is indicated for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.
Ryoncil® Remestemcel-L-rknd
Revumenib is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.
Revumenib Revuforj®
is FDA approved for the treatment of:Adult patients with non-Hodgkin lymphoma (NHL)Relapsed or refractory, low grade or follicular, CD20-positive Bcell NHL as a single agent.Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to RITUXAN in combination with chemotherapy, as single-agent maintenance therapy.Non-progressing (including stable disease), low-grade, CD20- positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.Adult patients with chronic lymphocytic leukemia (CLL)Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
Rituxan® Rituximab Truxima® * Rituximab-abbs* Ruxience™ * Rituximab-pvvr* Riabni Rituximab-arrx*
Rituximab and hyaluronidase human
Rituximab and hyaluronidase human is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:Follicular Lymphoma (FL)Relapsed or refractory, follicular lymphoma as a single agentPreviously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single agent maintenance therapyNon-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapyDiffuse Large B-cell Lymphoma (DLBCL) Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimensChronic Lymphocytic Leukemia (CLL) Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC)Limitations of Use:Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion.
Rituxan Hycela® Rituximab and hyaluronidase human
Romidepsin is FDA approved for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy and treatment of patients with peripheral T-cell lymphoma (PTCL) who have received at least one prior therapy.
Istodax® Romidepsin
Ruxolitinib is FDA approved for treatment of Intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adultsPolycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyureaSteroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and olderChronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Jakafi® Ruxolitinib